https://www.newsletter.the4mm.com/ 2025-10-25 https://www.newsletter.the4mm.com/archive 2025-06-16 https://www.newsletter.the4mm.com/subscribe 2025-10-25 https://www.newsletter.the4mm.com/authors 2026-04-03 https://www.newsletter.the4mm.com/authors/ashar-dhana 2025-03-28 https://www.newsletter.the4mm.com/forms/8c837da2-5d93-432d-9224-ba5c5ac9d55b 2025-07-12 https://www.newsletter.the4mm.com/forms/34f319eb-d721-4481-a0b6-80eb1c69a2cc 2025-07-11 https://www.newsletter.the4mm.com/forms/ac8a22dd-6528-414b-bdb9-554ab4c4de28 2025-07-13 https://www.newsletter.the4mm.com/p/anti-pd-1-win-for-desmoplastic-melanoma 2025-09-19 https://www.newsletter.the4mm.com/p/new-hs-pill-hpv-vaccine-for-aks-and-acne-led-devices 2025-09-19 https://www.newsletter.the4mm.com/p/100-response-icotrokinra-gains-and-vitiligo-combination-50589ef6c28ec00c 2025-09-19 https://www.newsletter.the4mm.com/p/a-first-for-chronic-hand-eczema 2025-09-19 https://www.newsletter.the4mm.com/p/tralokinumab-for-atopic-hand-eczema 2025-11-29 https://www.newsletter.the4mm.com/p/first-single-treatment-eb-gene-therapy-approved 2025-09-19 https://www.newsletter.the4mm.com/p/t-cell-melanoma-trial-triple-site-regrowth-and-dupilumab-in-pregnancy-80543bb327303f4d 2025-09-19 https://www.newsletter.the4mm.com/p/landmark-syphilis-trial 2025-09-20 https://www.newsletter.the4mm.com/p/new-long-acting-il13-antibody-for-eczema 2025-09-19 https://www.newsletter.the4mm.com/p/melanoma-imaging-miss-100-psoriasis-clearance-and-sofdra-works 2025-09-19 https://www.newsletter.the4mm.com/p/first-evidence-hpv-can-cause-cscc 2025-09-19 https://www.newsletter.the4mm.com/p/two-firsts-in-scc-landmark-botox-trial-and-ucenprubart-for-ad 2025-09-19 https://www.newsletter.the4mm.com/p/anti-kit-in-csu-povorcitinib-for-vitiligo-and-guselkumab-in-psa 2025-09-19 https://www.newsletter.the4mm.com/p/first-csu-approval-in-a-decade 2025-09-19 https://www.newsletter.the4mm.com/p/upadacitinib-advances-in-vitiligo 2025-11-08 https://www.newsletter.the4mm.com/p/t-cell-engager-for-immune-reset 2025-11-01 https://www.newsletter.the4mm.com/p/first-fda-approved-biologic-for-bp 2025-09-19 https://www.newsletter.the4mm.com/p/anti-ox40l-falls-short-in-eczema-trial 2025-09-13 https://www.newsletter.the4mm.com/p/a-first-for-high-risk-cutaneous-scc 2025-10-24 https://www.newsletter.the4mm.com/p/new-agent-for-dialysis-associated-pruritus 2025-09-19 https://www.newsletter.the4mm.com/p/opzelura-in-pediatric-ad-ai-melanoma-launch-and-cabtreo-vs-epiduo-forte 2025-09-19 https://www.newsletter.the4mm.com/p/sonelokimab-stumbles-in-pivotal-hs-trials 2025-10-11 https://www.newsletter.the4mm.com/p/car-t-for-autoimmune-disease 2025-11-21 https://www.newsletter.the4mm.com/p/eczema-trial-tests-bathing-frequency 2025-11-22 https://www.newsletter.the4mm.com/p/next-generation-tyk2-for-psoriasis 2025-09-19 https://www.newsletter.the4mm.com/p/first-oral-fasn-inhibitor-for-acne 2025-09-19 https://www.newsletter.the4mm.com/p/new-ai-model-for-dermatology 2025-09-19 https://www.newsletter.the4mm.com/p/first-itk-blocker-in-atopic-dermatitis 2025-09-19 https://www.newsletter.the4mm.com/p/30-year-first-for-alopecia 2025-12-13 https://www.newsletter.the4mm.com/p/three-fda-dermatology-approvals 2025-10-04 https://www.newsletter.the4mm.com/p/weekly-acne-agent-rosacea-pill-debuts-and-wart-clearance 2025-09-19 https://www.newsletter.the4mm.com/p/one-year-of-remibrutinib-in-csu 2025-10-25 https://www.newsletter.the4mm.com/p/first-in-class-treg-therapy-for-eczema 2025-09-19 https://www.newsletter.the4mm.com/p/biggest-updates-from-eadv-2025 2025-09-27 https://www.newsletter.the4mm.com/p/bp-breakthrough-oral-il-23-inhibitor-and-aad-2025 2025-09-19 https://www.newsletter.the4mm.com/p/first-4-in-1-psoriasis-trial-in-high-impact-sites 2025-09-06 https://www.newsletter.the4mm.com/p/zoryve-for-psoriasis-btk-inhibitors-miss-and-keloid-protocol-with-durable-results 2025-09-19